- Home
- VTVT vs CCEL Comparison
VTVT vs CCEL Comparison
Compare VTVT & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTVT
- CCEL
- Stock Information
- Founded
- VTVT 2015
- CCEL 1989
- Country
- VTVT United States
- CCEL United States
- Employees
- VTVT N/A
- CCEL N/A
- Industry
- VTVT Biotechnology: Pharmaceutical Preparations
- CCEL Managed Health Care
- Sector
- VTVT Health Care
- CCEL Health Care
- Exchange
- VTVT Nasdaq
- CCEL Nasdaq
- Market Cap
- VTVT 45.8M
- CCEL 39.9M
- IPO Year
- VTVT 2015
- CCEL 1997
- Fundamental
- Price
- VTVT $14.95
- CCEL $4.90
- Analyst Decision
- VTVT Strong Buy
- CCEL Strong Buy
- Analyst Count
- VTVT 2
- CCEL 1
- Target Price
- VTVT $35.50
- CCEL $8.50
- AVG Volume (30 Days)
- VTVT 3.2K
- CCEL 8.1K
- Earning Date
- VTVT 08-07-2025
- CCEL 07-15-2025
- Dividend Yield
- VTVT N/A
- CCEL 12.45%
- EPS Growth
- VTVT N/A
- CCEL N/A
- EPS
- VTVT N/A
- CCEL N/A
- Revenue
- VTVT $17,000.00
- CCEL $31,988,783.00
- Revenue This Year
- VTVT N/A
- CCEL $2.49
- Revenue Next Year
- VTVT N/A
- CCEL $0.95
- P/E Ratio
- VTVT N/A
- CCEL N/A
- Revenue Growth
- VTVT N/A
- CCEL 1.10
- 52 Week Low
- VTVT $12.58
- CCEL $4.68
- 52 Week High
- VTVT $26.99
- CCEL $9.43
- Technical
- Relative Strength Index (RSI)
- VTVT 38.23
- CCEL 47.88
- Support Level
- VTVT $15.52
- CCEL $4.80
- Resistance Level
- VTVT $17.46
- CCEL $5.24
- Average True Range (ATR)
- VTVT 0.47
- CCEL 0.27
- MACD
- VTVT -0.15
- CCEL 0.01
- Stochastic Oscillator
- VTVT 6.05
- CCEL 35.68
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.